Abstract
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling pathway has selective toxicity to malignant cells. The TRAIL receptors DR4 and DR5 are expressed at low levels in human umbilical cord blood cells (3–15%) and are upregulated by incubation with the cognate ligand, triggering apoptosis in 70–80% of receptor-positive cells (P<0.001). Apoptosis is not induced in hematopoietic progenitors, as determined from sustained severe combined immunodeficiency reconstituting potential and clonogenic activity. Furthermore, elimination of dead cells after incubation with TRAIL for 72 h results in a threefold enrichment in myeloid progenitors. Exposure to TRAIL in semisolid cultures showed synergistic activity of DR4 and granulocyte/macrophage colony-stimulating factor in recruiting lineage-negative (lin−) and CD34+ progenitors and in promoting the formation of large colonies. In murine bone marrow, ∼30% of lin− cells express TRAIL-R2 (the only murine receptor), and the receptor is upregulated after transplantation in cycling and differentiating donor cells that home to the host marrow. However, this receptor is almost ubiquitously expressed in the most primitive (lin−SCA-1+c-kit+) progenitors, and stimulates the clonogenic activity of lin− cells (P<0.001), suggesting a tropic function after transplantation. It is concluded that TRAIL does not trigger apoptosis in hematopoietic progenitors, and upregulation of its cognate receptors under stress conditions mediates tropic signaling that supports recovery from hypoplasia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aggarwal BB . Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745–756.
Di Pietro R, Zauli G . Emerging non-apoptotic functions of tumor necrosis factor related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331–340.
Zauli G, Secchiero P . The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006; 17: 245–257.
Secchiero P, Zauli G . Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008; 15: 42–48.
Carlo-Stella C, Lavazza C, Locatelli A, Viganò L, Gianni AM, Gianni L . Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007; 13: 2313–2317.
Henson ES, Johnston JB, Gibson SB . The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008; 49: 27–35.
Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A . TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280–288.
Song K, Benhaga N, Anderson RL, Khosravi-Far R . Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res 2006; 66: 6304–6311.
Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, Milanesi M et al. Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 2006; 17: 1225–1240.
Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008; 68: 9614–9623.
Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009; 106: 4822–4827.
Dempsey PW, Doyle SE, He JQ, Cheng G . The signalling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 193–209.
Gaur U, Aggarwal BB . Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66: 1403–1408.
Ware CF . The TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 181–184.
Falschlehner C, Emmerich CH, Gerlach B, Walczak H . TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462–1475.
Wilson NS, Dixit V, Ashkenazi A . Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10: 348–355.
De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999; 401: 489–493.
Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000; 95: 3716–3724.
Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Zauli G . TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004; 103: 517–522.
Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS . Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999; 59: 2770–2775.
Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2003; 278: 5444–5454.
Gazitt Y . TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817–1824.
Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002; 16: 67–73.
Lee NS, Cheong HJ, Kim SJ, Kim SE, Kim CK, Lee KT et al. Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. Leukemia 2003; 17: 1375–1383.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97: 1754–1759.
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.
Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005; 166: 557–563.
Kakagianni T, Giannakoulas NC, Thanopoulou E, Galani A, Michalopoulou S, Kouraklis-Symeonidis A et al. A probable role for TRAIL-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res 2006; 30: 713–721.
Greil R, Anether G, Johrer K, Tinhofer I . Tuning the rheostat of the myelopoietic system via Fas and TRAIL. Crit Rev Immunol 2003; 23: 301–322.
Testa U . Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004; 18: 1176–1199.
Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I et al. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells 2007; 25: 3194–3203.
Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I et al. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 2007; 35: 1601–1612.
Harris DT, LoCascio J, Besencon FJ . Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease. Bone Marrow Transplant 1994; 14: 545–553.
Song K, Chen Y, Göke R, Wilmen A, Seidel C, Göke A et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191: 1095–1104.
Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002; 8: 1433–1437.
Eaves C, Glimm H, Eisterer W, Audet J, Maguer-Satta V, Piret J . Characterization of human hematopoietic cells with short-lived in vivo repopulating activity. Ann NY Acad Sci 2001; 938: 63–70.
Manz MG . Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 2007; 26: 537–541.
Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002; 100: 2421–2429.
Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA . Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189: 1343–1354.
Zauli G, Rimondi E, Stea S, Baruffaldi F, Stebel M, Zerbinati C et al. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 2008; 214: 117–125.
Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 2008; 26: 2955–2963.
Brown JA, Boussiotis VA . Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008; 127: 286–297.
Baumann S, Zhu JY, Giaisi M, Treiber MK, Mahlknecht U, Krammer PH et al. Wogonin sensitizes resistant malignant cells to TNF{alpha}- and TRAIL-induced apoptosis. Blood 2006; 108: 3700–3706.
Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H et al. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells 2007; 25: 1448–1455.
Burroughs L, Storb R . Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Curr Opin Hematol 2005; 12: 45–54.
Resnick IB, Shapira MY, Slavin S . Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol 2005; 14: 207–219.
Yaniv I, Stein J . Reduced-intensity conditioning in children: a reappraisal in 2008. Bone Marrow Transplant 2008; 41 (Suppl 2): S18–S22.
Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J . Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 2009; 33: 255–259.
Acknowledgements
This work was funded by grants from the Frankel Trust for Experimental Bone Marrow Transplantation (JS, IY and NA) and the United States–Israel Binational Science Foundation (2003276 to NA and IY). We thank the technical staff for their outstanding support: Mrs Natalia Binkovsky, Mrs Ela Zuzovsky and Mrs Ana Zemlianski.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Mizrahi, K., Stein, J., Pearl-Yafe, M. et al. Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation. Leukemia 24, 1325–1334 (2010). https://doi.org/10.1038/leu.2010.97
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.97
Keywords
This article is cited by
-
A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors
Cellular & Molecular Immunology (2021)
-
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy
Cell Death & Differentiation (2016)
-
Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts
Bone Marrow Transplantation (2014)
-
Negative selection by apoptosis enriches progenitors in naïve and expanded human umbilical cord blood grafts
Bone Marrow Transplantation (2014)
-
Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro
Apoptosis (2012)